Oppenheimer raised the firm’s price target on Humana (HUM) to $260 from $250 and keeps an Outperform rating on the shares. The firm notes Humana reported a solid Q1 beat, driven by outperformance on cost-trend due to favorable underlying drivers, which continued into April. Oppenheimer is encouraged by the favorable outlook, but is also cautious given the early-year posture.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $270 from $220 at Truist
- Humana price target raised to $262 from $195 at UBS
- Humana price target raised to $269 from $252 at Guggenheim
- Humana Kept at Hold as Analyst Raises Price Target to $267 Amid Margin-Rebuild Focus and Uncertain Medical Cost Trends
- Humana price target raised to $180 from $176 at Barclays